Benjamin C Creelan
Overview
Explore the profile of Benjamin C Creelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1016
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mountzios G, Naidoo J, Wang C, Creelan B, Trotier D, Campbell T, et al.
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e432526.
PMID: 38781566
Chemoimmunotherapy is currently the preferred first-line treatment option for the majority of patients with advanced non-small cell lung cancer without driver genetic alterations. Most of these patients, however, will experience...
2.
Mills M, Uno A, Li P, Liveringhouse C, Kim Y, Oliver D, et al.
Clin Lung Cancer
. 2024 May;
25(5):417-423.e1.
PMID: 38719648
Background: EGFR-targeted therapy (ETT) and immune-checkpoint blockade (ICB) have shown promising results in treating NSCLC brain metastases (BM). However, little is known of their effect in treating leptomeningeal disease (LMD)....
3.
Szlosarek P, Creelan B, Sarkodie T, Nolan L, Taylor P, Olevsky O, et al.
JAMA Oncol
. 2024 Feb;
10(4):475-483.
PMID: 38358753
Importance: Arginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial...
4.
Dudek A, Xi M, Scilla K, Mamdani H, Creelan B, Saltos A, et al.
JTO Clin Res Rep
. 2023 Dec;
4(12):100584.
PMID: 38046376
Introduction: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent nivolumab in the second-line therapy of unresectable mesothelioma. Methods: This was a cooperative...
5.
Dohm A, Tang J, Mills M, Liveringhouse C, Sandoval M, Perez B, et al.
J Neurosurg
. 2023 Jan;
138(6):1600-1607.
PMID: 36681988
Objective: Immune checkpoint inhibitors (ICIs) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are commonly used in the systemic management of non-small cell lung cancer (NSCLC) brain metastases (BMs). However,...
6.
Naing A, Algazi A, Falchook G, Creelan B, Powderly J, Rosen S, et al.
Cancer
. 2022 Oct;
129(1):71-81.
PMID: 36309837
Background: Targeting programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO1) pathways is an appealing option for cancer treatment. Methods: The open-label, phase 1/2 ECHO-203 study evaluated the safety,...
7.
Creelan B, Wang C, Teer J, Toloza E, Yao J, Kim S, et al.
Nat Med
. 2021 Aug;
27(8):1410-1418.
PMID: 34385708
Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase...
8.
Berry D, Wang X, Michalski S, Kang H, Yang S, Creelan B, et al.
JCO Precis Oncol
. 2021 Jun;
4.
PMID: 34164592
No abstract available.
9.
Shields M, Hicks J, Boyle T, Haura E, Creelan B
J Thorac Oncol
. 2021 Mar;
16(3):e15-e17.
PMID: 33641722
No abstract available.
10.
Creelan B, Yeh T, Kim S, Nogami N, Kim D, Chow L, et al.
Br J Cancer
. 2020 Oct;
124(2):383-390.
PMID: 33012782
Background: EGFR tyrosine kinase inhibitors (TKIs) induce cytolysis and release of tumour proteins, which can stimulate antigen-specific T cells. The safety and efficacy of durvalumab and gefitinib in combination for...